The global market for Radiopharmaceutical (Oral Route) was estimated to be worth US$ 6761 million in 2023 and is forecast to a readjusted size of US$ 8804.1 million by 2030 with a CAGR of 3.9% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceutical (Oral Route), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Radiopharmaceutical (Oral Route) by region & country, by Type, and by Application.
The Radiopharmaceutical (Oral Route) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceutical (Oral Route).
麻豆原创 Segmentation
By Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Segment by Type:
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Segment by Application
Oncology
Cardiology
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Radiopharmaceutical (Oral Route) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Radiopharmaceutical (Oral Route) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Radiopharmaceutical (Oral Route) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Radiopharmaceutical (Oral Route) Product Introduction
1.2 Global Radiopharmaceutical (Oral Route) 麻豆原创 Size Forecast
1.2.1 Global Radiopharmaceutical (Oral Route) Sales Value (2019-2030)
1.2.2 Global Radiopharmaceutical (Oral Route) Sales Volume (2019-2030)
1.2.3 Global Radiopharmaceutical (Oral Route) Sales Price (2019-2030)
1.3 Radiopharmaceutical (Oral Route) 麻豆原创 Trends & Drivers
1.3.1 Radiopharmaceutical (Oral Route) Industry Trends
1.3.2 Radiopharmaceutical (Oral Route) 麻豆原创 Drivers & Opportunity
1.3.3 Radiopharmaceutical (Oral Route) 麻豆原创 Challenges
1.3.4 Radiopharmaceutical (Oral Route) 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Radiopharmaceutical (Oral Route) Players Revenue Ranking (2023)
2.2 Global Radiopharmaceutical (Oral Route) Revenue by Company (2019-2024)
2.3 Global Radiopharmaceutical (Oral Route) Players Sales Volume Ranking (2023)
2.4 Global Radiopharmaceutical (Oral Route) Sales Volume by Company Players (2019-2024)
2.5 Global Radiopharmaceutical (Oral Route) Average Price by Company (2019-2024)
2.6 Key Manufacturers Radiopharmaceutical (Oral Route) Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Radiopharmaceutical (Oral Route) Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Radiopharmaceutical (Oral Route)
2.9 Radiopharmaceutical (Oral Route) 麻豆原创 Competitive Analysis
2.9.1 Radiopharmaceutical (Oral Route) 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Radiopharmaceutical (Oral Route) Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceutical (Oral Route) as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Actinium-225
3.1.2 Lutetium-177
3.1.3 Radium-223
3.1.4 Holmium-166
3.1.5 Other
3.2 Global Radiopharmaceutical (Oral Route) Sales Value by Type
3.2.1 Global Radiopharmaceutical (Oral Route) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Radiopharmaceutical (Oral Route) Sales Value, by Type (2019-2030)
3.2.3 Global Radiopharmaceutical (Oral Route) Sales Value, by Type (%) (2019-2030)
3.3 Global Radiopharmaceutical (Oral Route) Sales Volume by Type
3.3.1 Global Radiopharmaceutical (Oral Route) Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Radiopharmaceutical (Oral Route) Sales Volume, by Type (2019-2030)
3.3.3 Global Radiopharmaceutical (Oral Route) Sales Volume, by Type (%) (2019-2030)
3.4 Global Radiopharmaceutical (Oral Route) Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology
4.1.2 Cardiology
4.1.3 Other
4.2 Global Radiopharmaceutical (Oral Route) Sales Value by Application
4.2.1 Global Radiopharmaceutical (Oral Route) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Radiopharmaceutical (Oral Route) Sales Value, by Application (2019-2030)
4.2.3 Global Radiopharmaceutical (Oral Route) Sales Value, by Application (%) (2019-2030)
4.3 Global Radiopharmaceutical (Oral Route) Sales Volume by Application
4.3.1 Global Radiopharmaceutical (Oral Route) Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Radiopharmaceutical (Oral Route) Sales Volume, by Application (2019-2030)
4.3.3 Global Radiopharmaceutical (Oral Route) Sales Volume, by Application (%) (2019-2030)
4.4 Global Radiopharmaceutical (Oral Route) Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Radiopharmaceutical (Oral Route) Sales Value by Region
5.1.1 Global Radiopharmaceutical (Oral Route) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Radiopharmaceutical (Oral Route) Sales Value by Region (2019-2024)
5.1.3 Global Radiopharmaceutical (Oral Route) Sales Value by Region (2025-2030)
5.1.4 Global Radiopharmaceutical (Oral Route) Sales Value by Region (%), (2019-2030)
5.2 Global Radiopharmaceutical (Oral Route) Sales Volume by Region
5.2.1 Global Radiopharmaceutical (Oral Route) Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Radiopharmaceutical (Oral Route) Sales Volume by Region (2019-2024)
5.2.3 Global Radiopharmaceutical (Oral Route) Sales Volume by Region (2025-2030)
5.2.4 Global Radiopharmaceutical (Oral Route) Sales Volume by Region (%), (2019-2030)
5.3 Global Radiopharmaceutical (Oral Route) Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
5.4.2 North America Radiopharmaceutical (Oral Route) Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
5.5.2 Europe Radiopharmaceutical (Oral Route) Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
5.6.2 Asia Pacific Radiopharmaceutical (Oral Route) Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
5.7.2 South America Radiopharmaceutical (Oral Route) Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
5.8.2 Middle East & Africa Radiopharmaceutical (Oral Route) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Radiopharmaceutical (Oral Route) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Radiopharmaceutical (Oral Route) Sales Value
6.2.1 Key Countries/Regions Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
6.2.2 Key Countries/Regions Radiopharmaceutical (Oral Route) Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
6.3.2 United States Radiopharmaceutical (Oral Route) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Radiopharmaceutical (Oral Route) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
6.4.2 Europe Radiopharmaceutical (Oral Route) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Radiopharmaceutical (Oral Route) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
6.5.2 China Radiopharmaceutical (Oral Route) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Radiopharmaceutical (Oral Route) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
6.6.2 Japan Radiopharmaceutical (Oral Route) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Radiopharmaceutical (Oral Route) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
6.7.2 South Korea Radiopharmaceutical (Oral Route) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Radiopharmaceutical (Oral Route) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
6.8.2 Southeast Asia Radiopharmaceutical (Oral Route) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Radiopharmaceutical (Oral Route) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Radiopharmaceutical (Oral Route) Sales Value, 2019-2030
6.9.2 India Radiopharmaceutical (Oral Route) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Radiopharmaceutical (Oral Route) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bracco Imaging
7.1.1 Bracco Imaging Company Information
7.1.2 Bracco Imaging Introduction and Business Overview
7.1.3 Bracco Imaging Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Bracco Imaging Radiopharmaceutical (Oral Route) Product Offerings
7.1.5 Bracco Imaging Recent Development
7.2 Bayer
7.2.1 Bayer Company Information
7.2.2 Bayer Introduction and Business Overview
7.2.3 Bayer Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Bayer Radiopharmaceutical (Oral Route) Product Offerings
7.2.5 Bayer Recent Development
7.3 Mallinckrodt
7.3.1 Mallinckrodt Company Information
7.3.2 Mallinckrodt Introduction and Business Overview
7.3.3 Mallinckrodt Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Mallinckrodt Radiopharmaceutical (Oral Route) Product Offerings
7.3.5 Mallinckrodt Recent Development
7.4 Nordion
7.4.1 Nordion Company Information
7.4.2 Nordion Introduction and Business Overview
7.4.3 Nordion Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Nordion Radiopharmaceutical (Oral Route) Product Offerings
7.4.5 Nordion Recent Development
7.5 Triad Isotopes
7.5.1 Triad Isotopes Company Information
7.5.2 Triad Isotopes Introduction and Business Overview
7.5.3 Triad Isotopes Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Triad Isotopes Radiopharmaceutical (Oral Route) Product Offerings
7.5.5 Triad Isotopes Recent Development
7.6 Lantheus
7.6.1 Lantheus Company Information
7.6.2 Lantheus Introduction and Business Overview
7.6.3 Lantheus Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Lantheus Radiopharmaceutical (Oral Route) Product Offerings
7.6.5 Lantheus Recent Development
7.7 IBA Group
7.7.1 IBA Group Company Information
7.7.2 IBA Group Introduction and Business Overview
7.7.3 IBA Group Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.7.4 IBA Group Radiopharmaceutical (Oral Route) Product Offerings
7.7.5 IBA Group Recent Development
7.8 GE Healthcare
7.8.1 GE Healthcare Company Information
7.8.2 GE Healthcare Introduction and Business Overview
7.8.3 GE Healthcare Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.8.4 GE Healthcare Radiopharmaceutical (Oral Route) Product Offerings
7.8.5 GE Healthcare Recent Development
7.9 China Isotope & Radiation
7.9.1 China Isotope & Radiation Company Information
7.9.2 China Isotope & Radiation Introduction and Business Overview
7.9.3 China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.9.4 China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Offerings
7.9.5 China Isotope & Radiation Recent Development
7.10 Jubilant Pharma
7.10.1 Jubilant Pharma Company Information
7.10.2 Jubilant Pharma Introduction and Business Overview
7.10.3 Jubilant Pharma Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Jubilant Pharma Radiopharmaceutical (Oral Route) Product Offerings
7.10.5 Jubilant Pharma Recent Development
7.11 Eli Lilly
7.11.1 Eli Lilly Company Information
7.11.2 Eli Lilly Introduction and Business Overview
7.11.3 Eli Lilly Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Eli Lilly Radiopharmaceutical (Oral Route) Product Offerings
7.11.5 Eli Lilly Recent Development
7.12 Advanced Accelerator Applications
7.12.1 Advanced Accelerator Applications Company Information
7.12.2 Advanced Accelerator Applications Introduction and Business Overview
7.12.3 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Offerings
7.12.5 Advanced Accelerator Applications Recent Development
7.13 SIEMENS
7.13.1 SIEMENS Company Information
7.13.2 SIEMENS Introduction and Business Overview
7.13.3 SIEMENS Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.13.4 SIEMENS Radiopharmaceutical (Oral Route) Product Offerings
7.13.5 SIEMENS Recent Development
7.14 Dongcheng
7.14.1 Dongcheng Company Information
7.14.2 Dongcheng Introduction and Business Overview
7.14.3 Dongcheng Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Dongcheng Radiopharmaceutical (Oral Route) Product Offerings
7.14.5 Dongcheng Recent Development
7.15 Navidea
7.15.1 Navidea Company Information
7.15.2 Navidea Introduction and Business Overview
7.15.3 Navidea Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Navidea Radiopharmaceutical (Oral Route) Product Offerings
7.15.5 Navidea Recent Development
8 Industry Chain Analysis
8.1 Radiopharmaceutical (Oral Route) Industrial Chain
8.2 Radiopharmaceutical (Oral Route) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Radiopharmaceutical (Oral Route) Sales Model
8.5.2 Sales Channel
8.5.3 Radiopharmaceutical (Oral Route) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
听
听
*If Applicable.